

RECEIVED

JUN 20 2003



TECH CENTER 1600/2900

1600

RAW SEQUENCE LISTING

DATE: 06/13/2003

PATENT APPLICATION: US/09/017,735B

TIME: 10:36:58

Input Set : E:\39963-20008.txt

Output Set: N:\CRF4\06132003\I017735B.raw

4 <110> APPLICANT: EPIMMUNE, Inc.
5 Grey, Howard
6 Sette, Alessandro
7 Sidney, John
8 Southwood, Scott
10 <120> TITLE OF INVENTION: HLA-A2.1 BINDING PEPTIDES AND THEIR USES
13 <130> FILE REFERENCE: 39963-20008.20
15 <140> CURRENT APPLICATION NUMBER: US 09/017,735B
16 <141> CURRENT FILING DATE: 1998-02-03
18 <150> PRIOR APPLICATION NUMBER: US 08/589,108
19 <151> PRIOR FILING DATE: 1996-01-23
21 <160> NUMBER OF SEQ ID NOS: 195
23 <170> SOFTWARE: FastSEQ for Windows Version 4.0
25 <210> SEQ ID NO: 1
26 <211> LENGTH: 9
27 <212> TYPE: PRT
28 <213> ORGANISM: Artificial Sequence
30 <220> FEATURE:
31 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 641
33 <400> SEQUENCE: 1
34 Phe Leu Tyr Asn Arg Pro Leu Ser Val
35 1 5
37 <210> SEQ ID NO: 2
38 <211> LENGTH: 9
39 <212> TYPE: PRT
40 <213> ORGANISM: Artificial Sequence
42 <220> FEATURE:
43 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 818
45 <400> SEQUENCE: 2
46 Val Leu Leu Pro Ser Leu Phe Leu Leu
47 1 5
49 <210> SEQ ID NO: 3
50 <211> LENGTH: 9
51 <212> TYPE: PRT
52 <213> ORGANISM: Artificial Sequence
54 <220> FEATURE:
55 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 819
57 <400> SEQUENCE: 3
58 Leu Leu Pro Ser Leu Phe Leu Leu Leu
59 1 5
61 <210> SEQ ID NO: 4
62 <211> LENGTH: 9
63 <212> TYPE: PRT

p.6
ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735B

DATE: 06/13/2003

TIME: 10:36:58

Input Set : E:\39963-20008.txt

Output Set: N:\CRF4\06132003\I017735B.raw

```

64 <213> ORGANISM: Artificial Sequence
66 <220> FEATURE:
67 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 514
69 <400> SEQUENCE: 4
70 Phe Val Asp Tyr Asn Phe Thr Ile Val
71 1 5
73 <210> SEQ ID NO: 5
74 <211> LENGTH: 9
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 89
81 <400> SEQUENCE: 5
82 Lys Leu Phe Pro Glu Val Ile Asp Leu
83 1 5
85 <210> SEQ ID NO: 6
86 <211> LENGTH: 10
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial Sequence
90 <220> FEATURE:
91 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 824
93 <400> SEQUENCE: 6
94 Phe Leu Leu Leu Gly Leu Trp Gly Phe Ala
95 1 5 10
97 <210> SEQ ID NO: 7
98 <211> LENGTH: 10
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
102 <220> FEATURE:
103 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 818
105 <400> SEQUENCE: 7
106 Val Leu Leu Pro Ser Leu Phe Leu Leu Leu
107 1 5 10
109 <210> SEQ ID NO: 8
110 <211> LENGTH: 10
111 <212> TYPE: PRT
112 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 398
117 <400> SEQUENCE: 8
118 Leu Leu Tyr Ser Asp Asp Ala Leu His Leu
119 1 5 10
121 <210> SEQ ID NO: 9
122 <211> LENGTH: 9
123 <212> TYPE: PRT
124 <213> ORGANISM: Artificial Sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: Immunogenic peptide from MT 32k 178
129 <400> SEQUENCE: 9

```

RAW SEQUENCE LISTING

DATE: 06/13/2003

PATENT APPLICATION: US/09/017,735B

TIME: 10:36:58

Input Set : E:\39963-20008.txt

Output Set: N:\CRF4\06132003\I017735B.raw

130 Ala Ile Tyr His Pro Gln Gln Phe Val
 131 1 5
 133 <210> SEQ ID NO: 10
 134 <211> LENGTH: 9
 135 <212> TYPE: PRT
 136 <213> ORGANISM: Artificial Sequence
 138 <220> FEATURE:
 139 <223> OTHER INFORMATION: Immunogenic peptide from MT 85c 317
 141 <400> SEQUENCE: 10
 142 Ala Met Lys Ala Asp Ile Gln His Val
 143 1 5
 145 <210> SEQ ID NO: 11
 146 <211> LENGTH: 9
 147 <212> TYPE: PRT
 148 <213> ORGANISM: Artificial Sequence
 150 <220> FEATURE:
 151 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 285
 153 <400> SEQUENCE: 11
 154 Ala Met Leu Gln Asp Met Ala Ile Leu
 155 1 5
 157 <210> SEQ ID NO: 12
 158 <211> LENGTH: 9
 159 <212> TYPE: PRT
 160 <213> ORGANISM: Artificial Sequence
 162 <220> FEATURE:
 163 <223> OTHER INFORMATION: Immunogenic peptide from MT superoxide dismutase
 164 160
 166 <400> SEQUENCE: 12
 167 Asp Met Trp Glu His Ala Phe Tyr Leu
 168 1 5
 170 <210> SEQ ID NO: 13
 171 <211> LENGTH: 9
 172 <212> TYPE: PRT
 173 <213> ORGANISM: Artificial Sequence
 175 <220> FEATURE:
 176 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 509
 178 <400> SEQUENCE: 13
 179 Gly Leu Phe Leu Thr Thr Glu Ala Val
 180 1 5
 182 <210> SEQ ID NO: 14
 183 <211> LENGTH: 9
 184 <212> TYPE: PRT
 185 <213> ORGANISM: Artificial Sequence
 187 <220> FEATURE:
 188 <223> OTHER INFORMATION: Immunogenic peptide from MT alanine dehydrogenase
 189 92
 191 <400> SEQUENCE: 14
 192 Ile Leu Phe Thr Phe Leu His Leu Ala
 193 1 5

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735B

DATE: 06/13/2003

TIME: 10:36:58

Input Set : E:\39963-20008.txt

Output Set: N:\CRF4\06132003\I017735B.raw

195 <210> SEQ ID NO: 15
196 <211> LENGTH: 9
197 <212> TYPE: PRT
198 <213> ORGANISM: Artificial Sequence
200 <220> FEATURE:
201 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 369
203 <400> SEQUENCE: 15
204 Lys Leu Ala Gly Gly Val Ala Val Ile
205 1 5
207 <210> SEQ ID NO: 16
208 <211> LENGTH: 9
209 <212> TYPE: PRT
210 <213> ORGANISM: Artificial Sequence
212 <220> FEATURE:
213 <223> OTHER INFORMATION: Immunogenic peptide from MT 85B 15
215 <400> SEQUENCE: 16
216 Leu Met Ile Gly Thr Ala Ala Val
217 1 5
219 <210> SEQ ID NO: 17
220 <211> LENGTH: 9
221 <212> TYPE: PRT
222 <213> ORGANISM: Artificial Sequence
224 <220> FEATURE:
225 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 286
227 <400> SEQUENCE: 17
228 Met Leu Gln Asp Met Ala Ile Leu Thr
229 1 5
231 <210> SEQ ID NO: 18
232 <211> LENGTH: 9
233 <212> TYPE: PRT
234 <213> ORGANISM: Artificial Sequence
236 <220> FEATURE:
237 <223> OTHER INFORMATION: Immunogenic peptide from MT 85B 14
239 <400> SEQUENCE: 18
240 Arg Leu Met Ile Gly Thr Ala Ala Ala
241 1 5
243 <210> SEQ ID NO: 19
244 <211> LENGTH: 9
245 <212> TYPE: PRT
246 <213> ORGANISM: Artificial Sequence
248 <220> FEATURE:
249 <223> OTHER INFORMATION: Immunogenic peptide from MT 32k 178
251 Immunogenic peptide from MT 32k 25
253 <400> SEQUENCE: 19
254 Arg Leu Val Ser Gly Leu Val Gly Ala
255 1 5
257 <210> SEQ ID NO: 20
258 <211> LENGTH: 9
259 <212> TYPE: PRT

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735B

DATE: 06/13/2003

TIME: 10:36:58

Input Set : E:\39963-20008.txt

Output Set: N:\CRF4\06132003\I017735B.raw

260 <213> ORGANISM: Artificial Sequence
262 <220> FEATURE:
263 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 318
265 <400> SEQUENCE: 20
266 Arg Met Pro Ala Val Thr Asp Leu Val
267 1 5
269 <210> SEQ ID NO: 21
270 <211> LENGTH: 9
271 <212> TYPE: PRT
272 <213> ORGANISM: Artificial Sequence
274 <220> FEATURE:
275 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 179
277 <400> SEQUENCE: 21
278 Ser Leu Leu Glu Ile Gly Glu Gly Val
279 1 5
281 <210> SEQ ID NO: 22
282 <211> LENGTH: 9
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 363
289 <400> SEQUENCE: 22
290 Val Leu Leu Leu Asp Val Thr Pro Leu
291 1 5
293 <210> SEQ ID NO: 23
294 <211> LENGTH: 9
295 <212> TYPE: PRT
296 <213> ORGANISM: Artificial Sequence
298 <220> FEATURE:
299 <223> OTHER INFORMATION: Immunogenic peptide from MT 85c 137
301 <400> SEQUENCE: 23
302 Tyr Thr Tyr Lys Trp Glu Thr Phe Leu
303 1 5
305 <210> SEQ ID NO: 24
306 <211> LENGTH: 9
307 <212> TYPE: PRT
308 <213> ORGANISM: Artificial Sequence
310 <220> FEATURE:
311 <223> OTHER INFORMATION: Immunogenic peptide from Lassa gp 343
313 <400> SEQUENCE: 24
314 Ala Leu Ile Asn Asp Gln Leu Ile Met
315 1 5
317 <210> SEQ ID NO: 25
318 <211> LENGTH: 9
319 <212> TYPE: PRT
320 <213> ORGANISM: Artificial Sequence
322 <220> FEATURE:
323 <223> OTHER INFORMATION: Immunogenic peptide from Lassa Josiah(NP) 376
325 <400> SEQUENCE: 25

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/017,735B

DATE: 06/13/2003
TIME: 10:36:59

Input Set : E:\39963-20008.txt
Output Set: N:\CRF4\06132003\I017735B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:192; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11
Seq#:193; Xaa Pos. 1,2,3,4,5,6,7,8,9,10
Seq#:194; Xaa Pos. 1,2,3,4,5,6,7,8,9
Seq#:195; Xaa Pos. 1,2,3,4,5,6,7,8